A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia
Journal article
Jarskog, L. Fredrik, Pedersen, Cort A., Johnson, Jacqueline L., Hamer, Robert M., Rau, Shane W., Elliott, Tonya and Penn, David L.. (2017). A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia. Schizophrenia Research. 185, pp. 88-95. https://doi.org/10.1016/j.schres.2017.01.008
Authors | Jarskog, L. Fredrik, Pedersen, Cort A., Johnson, Jacqueline L., Hamer, Robert M., Rau, Shane W., Elliott, Tonya and Penn, David L. |
---|---|
Abstract | Social cognition is impaired in people with schizophrenia and these deficits are strongly correlated with social functioning. Oxytocin is a hypothalamic peptide that contributes to maternal infant bonding and has diverse pro-social effects in adults. This study tested the hypothesis that 12 weeks of intranasal oxytocin will improve social cognitive function in outpatients with schizophrenia and schizoaffective disorder. Sixty-eight eligible participants were randomized to oxytocin (24 IU twice daily) or placebo. Social cognitive function was assessed using the Emotion Recognition-40, Brüne Theory of Mind, Reading the Mind in the Eyes test, Trustworthiness task and Ambiguous Intentions Hostility Questionnaire at baseline, 6 weeks and 12 weeks. In addition, social function was assessed using the Specific Levels of Functioning Scale and a role-play test, and psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Fifty-five participants completed the 12-week trial. The study found no evidence for a differential advantage of oxytocin over placebo on social cognition. Among secondary outcomes, there was a modest advantage for oxytocin over placebo on a component of social functioning, although there was also evidence that the placebo group outperformed the oxytocin group on the role-play task. No between-group differences emerged on measures of psychopathology in pre-specified comparisons, but oxytocin showed significant within-group reduction in PANSS negative symptoms and significant between-group improvement in negative symptoms in the schizophrenia subgroup. Further testing is needed to clarify whether oxytocin has therapeutic potential for social cognitive deficits and/or negative symptoms in people with schizophrenia. |
Keywords | oxytocin; social cognition; psychosis; schizophrenia; schizoaffective disorder; negative symptoms |
Year | 2017 |
Journal | Schizophrenia Research |
Journal citation | 185, pp. 88-95 |
Publisher | Elsevier B.V. |
ISSN | 0920-9964 |
Digital Object Identifier (DOI) | https://doi.org/10.1016/j.schres.2017.01.008 |
PubMed ID | 28094169 |
Scopus EID | 2-s2.0-85009739463 |
PubMed Central ID | PMC5474129 |
Open access | Published as green open access |
Page range | 88-95 |
Funder | National Institute of Mental Health (NIMH), United States of America |
Author's accepted manuscript | License File Access Level Open |
Publisher's version | File Access Level Controlled |
Output status | Published |
Publication dates | |
Online | 13 Jan 2017 |
Publication process dates | |
Accepted | 04 Jan 2017 |
Grant ID | R01MH093529 |
https://acuresearchbank.acu.edu.au/item/852w7/a-12-week-randomized-controlled-trial-of-twice-daily-intranasal-oxytocin-for-social-cognitive-deficits-in-people-with-schizophrenia
Download files
Author's accepted manuscript
AM_Jarskog_2017_A_12_week_randomized_controlled_trial.pdf | |
License: CC BY-NC-ND 4.0 | |
File access level: Open |
Restricted files
Publisher's version
82
total views97
total downloads0
views this month0
downloads this month